Physician profile
Jonathan M Greer
NPI 1003816281
$757,401.36
in general payments reported to CMS, 2019-2025
42 companies · $91K in 2025
The $91K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202K · 2020: $68K · 2021: $66K · 2022: $116K · 2023: $104K · 2024: $110K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $186K · Travel and Lodging: $41K · Honoraria: $33K · Consulting Fee: $25K · Food and Beverage: $20K · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185,689.50 |
| Travel and Lodging | $41,171.66 |
| Honoraria | $33,075.00 |
| Consulting Fee | $25,091.50 |
| Food and Beverage | $19,735.21 |
| Education | $193.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $218,072.87 | 2019-2025 | Evenity, Prolia, Enbrel |
| Janssen Scientific Affairs, LLC | $121,666.02 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Radius Health, INC. | $87,823.82 | 2019-2025 | Tymlos |
| Ucb, INC. | $83,586.28 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $79,822.72 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $63,666.16 | 2019-2025 | |
| Lilly USA, LLC | $36,045.81 | 2019-2024 | Taltz, Kisunla |
| Novartis Pharmaceuticals Corporation | $35,783.65 | 2019-2025 | |
| Horizon Therapeutics Plc | $15,417.08 | 2019-2023 | Krystexxa |
| Gilead Sciences, INC. | $5,364.04 | 2020 | |
| Sobi, INC | $2,581.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,586.86 | 2019-2025 | Benlysta, Nucala |
| Pfizer INC. | $1,226.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $949.48 | 2019-2025 | Orencia, Sotyktu |
| Astrazeneca Pharmaceuticals LP | $619.02 | 2022-2025 | Saphnelo |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.